You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.
Quest's CEO gave an overview of the firm's business and the lab space in general, while GenMark launched a new system this week aimed at smaller labs.
The firm plans to use $110 million of the net cash proceeds to pay down debt.
Several firms, such as Exact Sciences and Foundation Medicine, saw their share values more than double during the year, while NantHealth and GenMark saw their share values shrink.
The stock prices of 17 of the 25 firms in the 360Dx Index fell month over month with Enzo Biochem and Bio-Rad leading decliners.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
The firm's Group A Strep test for use on its Sofia2 analyzer also received CLIA waiver from the agency.
In a new business update, the firm also said it plans to sell and lease back an Abbott manufacturing facility in California for $147 million.
Quidel said that its board rejected offers by Danaher, the parent firm of Beckman Coulter, to acquire the BNP assay business after finding Danaher's proposal "inadequate."
The firm's molecular business also continued to grow, with a revenue increase of 13 percent.